Health :: HIV/AIDS

Online Extra: Woman who apparently beat HIV goes public

Online Extra: Woman who apparently beat HIV goes public

  • by Bob Roehr
  • Oct 16, 2019

Leading HIV researchers have come to believe that at least one person has found a way to naturally rid their body of the virus.

Online Extra: FDA approves new PrEP

Online Extra: FDA approves new PrEP

  • by Liz Highleyman
  • Oct 4, 2019

The federal Food and Drug Administration October 3 approved a new daily PrEP pill that could offer a safer option for some individuals at risk for HIV, but the indication does not cover everyone who could potentially benefit from the prevention medication

HIV may persist in brain despite treatment

HIV may persist in brain despite treatment

  • by Liz Highleyman
  • Jul 15, 2019

New study shows that HIV can remain in the fluid surrounding the brain even after a decade on antiretroviral treatment.

AIDS 2020 organizers seek $2M from CA

AIDS 2020 organizers seek $2M from CA

  • by Matthew S. Bajko
  • May 29, 2019

Organizers of the International AIDS Conference set to be co-hosted by San Francisco and Oakland next summer are seeking $2 million from the state.

Study confirms no transmissions with undetectable HIV

Study confirms no transmissions with undetectable HIV

  • by Liz Highleyman
  • May 20, 2019

The largest treatment-as-prevention study for gay and bisexual men confirms that people on antiretroviral therapy with undetectable viral load do not transmit HIV.

Gilead PrEP donation met with skepticism

Gilead PrEP donation met with skepticism

  • by David-Elijah Nahmod
  • May 15, 2019

Gilead Sciences announced last week it will donate millions of free bottles of Truvada for PrEP to the Centers for Disease Control and Prevention, but many AIDS activists say it is not enough.

Advocates say CDC has PrEP patents

Advocates say CDC has PrEP patents

  • by Liz Highleyman
  • Apr 24, 2019

The Centers for Disease Control and Prevention holds patents on the use of Truvada for HIV prevention, according to advocates, who want Gilead Sciences to pay future and retroactive royalties to make PrEP more widely available.

FDA approves new dual combo pill for HIV

FDA approves new dual combo pill for HIV

  • by Liz Highleyman
  • Apr 10, 2019

The U.S. Food and Drug Administration this week approved Dovato, a two-drug combination pill that provides a complete once-daily antiretroviral regimen for people starting HIV treatment for the first time.

PrEP pharmacy bill amended with 1-month prescription limit passes first legislative vote

PrEP pharmacy bill amended with 1-month prescription limit passes first legislative vote

  • by Matthew S. Bajko
  • Apr 8, 2019

A bill to make it easier for people to access PrEP via their local pharmacy survived its first committee vote April 8 after California lawmakers amended it to restrict the supply of the HIV prevention medication to one month.

On-demand PrEP failure reported

On-demand PrEP failure reported

  • by Liz Highleyman
  • Mar 27, 2019

An Australian man said he acquired HIV while taking on-demand PrEP before and after sex, which could represent the latest in a handful of cases of failure of the prevention pill.

Gaps in testing and treatment spur HIV transmission

Gaps in testing and treatment spur HIV transmission

  • by Liz Highleyman
  • Mar 27, 2019

Around 80 percent of new HIV infections are attributable to people who either do not know their status or are not receiving treatment to suppress viral load, according to a new report from the Centers for Disease Control and Prevention.

PrEP research highlighted at confab

PrEP research highlighted at confab

  • by Liz Highleyman
  • Mar 20, 2019

PrEP was a major topic at the Conference on Retroviruses and Opportunistic Infections this month in Seattle. Researchers showed that a new version of tenofovir works as well as the Truvada pill and offered insights about how gay and bisexual men are using

Project Inform expected to close

Project Inform expected to close

  • by Liz Highleyman
  • Mar 15, 2019

Project Inform, one of the nation's longest-running HIV education and advocacy organizations, has terminated its staff and is likely to cease operations, the Bay Area Reporter has learned.

HIV case may be a second cure

HIV case may be a second cure

  • by Liz Highleyman
  • Mar 6, 2019

A London man with long-term undetectable HIV despite stopping antiretroviral treatment a year and a half ago could potentially be the second case of an HIV cure, according to a report at the Conference on Retroviruses and Opportunistic Infections.